# MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

> **NCT04834024** · PHASE3 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 168 (estimated)

## Conditions studied

- Follicular Lymphoma and Marginal Zone Lymphoma

## Interventions

- **DRUG:** Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
- **DRUG:** lenalinomide

## Key facts

- **NCT ID:** NCT04834024
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-02
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834024, "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04834024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*